Bausch Health Announces Adoption of Shareholder Rights Plan
LAVAL, QC / ACCESS Newswire / April 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") announces today that its board of directors (the "Board") has approved the adoption of a shareholder rights plan (the "SRP") pursuant to a shareholder rights plan agreement entered into with TSX Trust Company, as rights agent, dated April 14, 2025 (the "Effective Date"). The SRP has been adopted to help ensure that all shareholders of the Company are treated fairly and equally in connection with any unsolicited take-over bid or other acquisition of control of the Company (including by way of a "creeping" take-over bid) and that the Board has the opportunity to identify, solicit, develop and negotiate value-enhancing alternatives to any unsolicited take-over bid or similar transaction.
Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program
Bausch Health is offering scholarships to six students impacted by dermatologic conditions, with application submissions open through June 11, 2025 LAVAL, QC / ACCESS Newswire / April 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC)and its dermatology business, Ortho Dermatologics, today announced the 2025 ASPIRE HIGHER Scholarship Program is now open for application submissions through June 11, 2025. The program will award six exceptional students, impacted by dermatologic conditions, a scholarship of up to $10,000 in support of their higher education goals.
Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris
LAVAL, QC / ACCESS Newswire / April 9, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that it has signed a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA) for Canadian public drug plan coverage for PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide) gel 1.2% w/w, 0.15% w/w and 3.1% w/w, a new triple-combination topical prescription treatment for acne vulgaris in patients 12 years of age and older.1 The letter of intent means Bausch Health, Canada Inc. can now proceed to finalizing individual listing agreements for CABTREO to be covered by each of Canada's government drug plans, including those of all provinces and territories and the federal government (including plans for veterans and Indigenous peoples). The letter of intent spells out the agreed terms of those listing agreements, given the participation of all Canadian public drug plans in the pCPA process.
Bausch Health: Repositioning Aplezin As First Oral Monotherapy For TRD A $3 Billion Opportunity
One-eighth of the global population and one-fifth of U.S. adults suffer from mental health conditions, highlighting an urgent need for better psychiatric care. Bausch Health's Aplenzin shows promise for treatment-resistant depression (TRD), potentially offering better efficacy and tolerability compared to Wellbutrin, addressing a significant unmet medical need. Repositioning Aplenzin for TRD could unlock a $3 billion market opportunity, aiding Bausch Health's financial recovery and providing substantial clinical benefits.
Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month
Bausch Health's gastroenterology business, Salix Pharmaceuticals, recognizes the complexities of irritable bowel syndrome (IBS) and seeks to make a difference in how the condition is perceived, diagnosed and treated. LAVAL, QC / ACCESS Newswire / April 2, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the launch of IBS Symptoms Aren't Black and White: Living in the Gray, an authentic storytelling campaign that addresses the complexities of living with irritable bowel syndrome (IBS).
Bausch + Lomb recalls some of its implantable eye lenses
Bausch + Lomb said on Thursday it will recall some of its implantable eye lenses after receiving reports of complications, the cause of which could not immediately be known.
Bausch + Lomb Recalls EnVista Intraocular Lenses
The Canadian eyecare company said Thursday that it has made a voluntary recall of its intraocular lenses on its enVista platform.
Bausch Health to Announce First Quarter Results on April 30
LAVAL, QC / ACCESS Newswire / March 27, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter financial results after market close on Wednesday, April 30, 2025. Bausch Health will host a conference call and live webcast at 5:00 p.m.
Bausch Health Announces Pricing of Upsized Private Offering of Senior Secured Notes
LAVAL, QC / ACCESS Newswire / March 25, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has priced its previously announced offering (the "Offering") of $4.4 billion aggregate principal amount of 10.000% senior secured notes due 2032 (the "Notes") through its indirect wholly-owned subsidiary, 1261229 B.C. Ltd. (the "Issuer"), a company incorporated under the laws of British Columbia, Canada (the "Issuer") that, at the closing of the transactions will be a non-guarantor restricted subsidiary under the indentures that govern the Company's existing senior notes.
Bausch Health Announces Conditional Redemption of Senior Notes
LAVAL, QC / ACCESS Newswire / March 21, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that (i) it has delivered conditional notices of redemption for all of its outstanding 5.500% Senior Secured Notes due 2025, 9.000% Senior Notes due 2025, 5.750% Senior Secured Notes due 2027 and 6.125% Senior Secured Notes due 2027 (collectively, the "BHC Notes") and (ii) 1375209 B.C. Ltd., the Company's indirect wholly-owned subsidiary ("HoldCo"), has delivered a conditional notice of redemption for all of its outstanding 9.000% Senior Secured Notes due 2028 (collectively with the BHC Notes, the "Notes").
Bausch Health Announces Launch of Private Offering of Senior Secured Notes and Conditional Redemption of Senior Notes
LAVAL, QC / ACCESS Newswire / March 19, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has launched an offering (the "Offering") of $4.0 billion aggregate principal amount of new senior secured notes due 2032 (the "Notes") through its indirect wholly-owned subsidiary, 1261229 B.C. Ltd., a company incorporated under the laws of British Columbia, Canada (the "Issuer") that, at the closing of the transactions will be a non-guarantor restricted subsidiary under the indentures that govern the Company's existing senior notes.
Bausch Health Announces Launch of Syndication of New Senior Secured Credit Facilities
Transaction is part of a broader refinancing initiative aimed at opportunistically accessing capital markets to address near- and mid-term maturities LAVAL, QC / ACCESS Newswire / March 19, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has launched the syndication of new senior secured credit facilities totaling at least $3.8 billion. The new senior secured credit facilities are expected to consist of (i) a 5-year senior secured revolving credit facility in an amount of at least $400 million (the "New Revolving Facility") and (ii) a $3,400 million 5.5-year secured term loan B facility (the "New Term Loan Facility" and, together with the New Revolving Facility, the "New Senior Secured Credit Facilities") through its indirect wholly-owned subsidiary, 1261229 B.C.
